Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but Not mTORC2

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension

(2010) Marc Mejias et al.   JOURNAL OF HEPATOLOGY

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis

(2010) Eleonora Patsenker et al.   JOURNAL OF HEPATOLOGY

Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways

(2009) Kim R. Bridle et al.   LIVER TRANSPLANTATION

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice

(2008) Anja M. Geerts et al.   HEPATOLOGY RESEARCH

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatic fibrosis—Overview

(2008) Scott L. Friedman   TOXICOLOGY

Phosphatidylinositol 3-kinase/Akt pathway regulates hepatic stellate cell apoptosis

(2008) Yan Wang et al.   WORLD JOURNAL OF GASTROENTEROLOGY